FDA records linked by MedtechLedger identify Shanghai United Imaging Healthcare Co., Ltd. as the applicant on one premarket notification and as the recalling firm on five device enforcement records. The clearance covers the uPMR Zenith, described in the FDA record as a tomographic imager combining emission computed tomography with nuclear magnetic resonance, classified in radiology under 21 CFR 892.1200 and product code OUO. The enforcement records concern CT and PET/CT systems with software. The company's own published material describes digital PET/CT and PET/MR portfolios and lists PET/CT, PET/MR, ultrasound, radiotherapy and life science instruments among its product categories. [1][2][7][8][9]
The uPMR Zenith clearance
K261676 was received on 21 May 2026 and decided on 28 October 2026 with decision code SESE, meaning substantially equivalent, under a Traditional submission reviewed by the radiology panel. The FDA record lists the applicant as Shanghai United Imaging Healthcare Co., Ltd. at a Chengbei Road, Jiading District, Shanghai address, with product code OUO and regulation number 892.1200. The device name is uPMR Zenith, and the openFDA device name field reads tomographic imager combining emission computed tomography with nuclear magnetic resonance. [1][9]
A third-party summary of the same clearance identifies the device's common name as a positron emission tomography and magnetic resonance imaging system, model uPMR Zenith, with a second product code, MOS, and names K234154, device uPMR 790, as the predicate. The same summary states that non-clinical testing including image performance tests was conducted to verify the device met design specifications as substantially equivalent. These are descriptions of filing content, not independent findings of clinical performance. [9][10]
Published product categories and conference activity
The company's 2025 annual report summary, published in English as a summary translation, lists product categories including PET/CT and PET/MR, color Doppler ultrasound diagnostic systems, medical linear accelerator systems and life science instruments. The same document notes an investor relations section on united-imaging.com. A company news item dated 31 May 2026 describes presenting molecular imaging advancements at the SNMMI 2026 Annual Meeting and highlighting digital PET/CT and PET/MR portfolios. [7][8]
How to read the record set
The linked collection holds one premarket notification, decided SESE, and the record sample contains that single entry, so the sample and the full collection coincide here. The five enforcement records appear in a separate recall sample and are not part of the clearance count. Neither count describes total company sales, total portfolio or safety performance; they reflect the filings linked as of 20 November 2026. [1][2][3][4][5]
The FDA filing address is a correspondence address on regulatory records and is not presented as a corporate headquarters. No parent, brand or ownership relationship is verified in these sources, and the applicant name is used as it appears on the filings. [1][2][9]







